share_log

UroGen Pharma Announced Topline Data From Phase 3 Trials ATLAS And ENVISION Studying UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer; Both Trials Met Primary Endpoints

Benzinga ·  Jul 27, 2023 21:54

-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 --

-- ENVISION Showed a Complete Response Rate of 79.2% at 3-Months --

-- Side Effect Profile in ATLAS and ENVISION Consistent with Previous Clinical Trials of UGN-102 --

-- UroGen Will Review ATLAS and ENVISION Top-line Data Today at 10:00 a.m. Eastern Time --

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment